Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000950170-25-038262·Aligos Therapeutics, Inc.
Schedule 13D ownership disclosure
Aligos Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 01626L204
Event date: 2025-03-10
- Filing-level shares
- 175,509
- Percent of class
- 3.2%
- Lawrence M. Blatt, Ph.D.Reported CIK 0001242110
Shares: 175,509 · Class: 3.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-038262
- Form type
- SCHEDULE 13D/A
- Filer
- Aligos Therapeutics, Inc.
- CIK
- CIK 1799448
- Filed
- Mar 12, 2025
- Reporting period
- Mar 10, 2025
- Description
- Schedule 13D beneficial ownership